Edition:
India

Ascendis Health Ltd (ASCJ.J)

ASCJ.J on Johannesburg Stock Exchange

493.00ZAc
24 May 2019
Change (% chg)

3.00 (+0.61%)
Prev Close
490.00
Open
470.00
Day's High
495.00
Day's Low
440.00
Volume
214,987
Avg. Vol
886,801
52-wk High
1,200.00
52-wk Low
305.00

Latest Key Developments (Source: Significant Developments)

Ascendis Health HY HEPS 37.9 Cents
Monday, 18 Mar 2019 

March 18 (Reuters) - Ascendis Health Ltd ::UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2018.HY GROUP REVENUE UP 3% TO R3.96 BILLION.DIRECTORS HAVE AGAIN ELECTED NOT TO DECLARE A DIVIDEND AND TO RETAIN CASH TO SETTLE DEBT OBLIGATIONS.INVOLVED IN ONGOING NEGOTIATIONS REGARDING POTENTIAL DISPOSAL OF REMEDICA, HAS EXTENDED PROCESS TO INCLUDE OTHER POTENTIAL BIDDERS.AFTER END OF REPORTING PERIOD, GROUP RECEIVED AN UNSOLICITED OFFER FOR REMEDICA BUSINESS UNIT IN CYPRUS.HY NORMALISED HEADLINE EARNINGS PER SHARE 69.0 CENTS.COMPLETION OF BIOSCIENCES TRANSACTION AND PROGRESSING REMEDICA OFFER ARE MAJOR PRIORITIES.GROUP'S STRATEGY WILL BE REVISED SHOULD REMEDICA BUSINESS BE SOLD.HY HEADLINE EARNINGS PER SHARE 37.9 CENTS.INVOLVED IN ONGOING NEGOTIATIONS REGARDING POTENTIAL DISPOSAL OF REMEDICA AND HAS EXTENDED PROCESS TO INCLUDE OTHER POTENTIAL BIDDERS.NEGOTIATIONS ARE AT VERY ADVANCED STAGE FOR SALE OF EFEKTO, MARLTONS AND AFRIKELP BUSINESSES WHICH FORM PART OF BIOSCIENCES DIVISION.REMAINING BUSINESS WITHIN BIOSCIENCES, AVIMA/KLUBM5, MAY BE CONSIDERED FOR DISPOSAL IN SHORT TO MEDIUM TERM.AGREEMENT WAS REACHED FOR SALE OF ASCENDIS DIRECT ON 10 SEPTEMBER 2018, HOWEVER SALE DID NOT MATERIALISE.NEGOTIATIONS WITH A POTENTIAL BUYER ARE CONTINUING FOR SALE OF ASCENDIS DIRECT.GOING FORWARD GROUP TO MANUFACTURE PHARMACEUTICAL PRODUCTS, CURRENTLY MANUFACTURED AT ISANDO VIA THIRD- PARTY MANUFACTURING DEAL.  Full Article

Ascendis Health Says HY Normalised Headline Earnings From Cont Ops Forecast To Decline By Between 4% And 9%
Friday, 8 Mar 2019 

March 8 (Reuters) - Ascendis Health Ltd ::VOLUNTARY TRADING STATEMENT, UPDATE ON STRATEGIC DIVESTMENTS AND FURTHER CAUTIONARY ANNOUNCEMENT.HY NORMALISED HEADLINE EARNINGS FROM CONTINUING OPERATIONS ARE FORECAST TO DECLINE BY BETWEEN 4% AND 9%.ASCENDIS HEALTH - BOARD HAS RESOLVED TO DISPOSE OF EFEKTO, MARLTONS AND AFRIKELP BUSINESSES AND NEGOTIATIONS FOR SALE ARE WELL ADVANCED.INVOLVED IN ONGOING NEGOTIATIONS REGARDING POTENTIAL DISPOSAL OF REMEDICA, WILL UPDATE INVESTORS SHOULD A TRANSACTION BE CONCLUDED.SEES HY TOTAL OPERATIONS HEPS BETWEEN 36.8 CENTS TO 38.7 CENTS.SEES HY TOTAL OPERATIONS NORMALISED HEPS BETWEEN 66.9 CENTS TO 70.4 CENTS.  Full Article

Ascendis Health Says Mergence Investment Managers Acquired Co's Shares
Wednesday, 13 Feb 2019 

Feb 14 (Reuters) - Ascendis Health Ltd ::ASCENDIS HEALTH LTD - MERGENCE INVESTMENT MANAGERS, ON BEHALF OF ITS CLIENTS, HAS ACQUIRED ASCENDIS ORDINARY SHARES.ASCENDIS HEALTH - MERGENCE INVESTMENT MANAGERS' BENEFICIAL INTEREST IN ASCENDIS NOW AMOUNTS TO 5.07% OF TOTAL NUMBER OF SHARES IN ISSUE.  Full Article

Ascendis Health Says Still In Talks Regarding Remedica Offer
Friday, 8 Feb 2019 

Feb 8 (Reuters) - Ascendis Health Ltd ::FURTHER CAUTIONARY ANNOUNCEMENT.SAYS INFORMATION SET OUT IN MEDIA ARTICLE PERTAINING TO VALUATION OF REMEDICA BUSINESS BY ASCENDIS IS "UNSUBSTANTIATED".BOARD OF DIRECTORS OF ASCENDIS IS STILL INVOLVED IN NEGOTIATIONS REGARDING REMEDICA OFFER.  Full Article

Ascendis Health Says Legae Peresec Now Holds 5.05 Pct Of Co's Total Shares In Issue
Wednesday, 6 Feb 2019 

Feb 6 (Reuters) - Ascendis Health Ltd ::LEGAE PERESEC (PROPRIETARY) LIMITED HAS ACQUIRED ASCENDIS ORDINARY SHARES.LEGAE PERESEC'S BENEFICIAL INTEREST IN ASCENDIS NOW AMOUNTS TO 5.05% OF TOTAL NUMBER OF SHARES IN ISSUE.  Full Article

Ascendis Health Says Ascendis Received Unsolicited Offer In Respect Of Remedica Business Unit
Monday, 14 Jan 2019 

Jan 14 (Reuters) - Ascendis Health Ltd ::CAUTIONARY ANNOUNCEMENT.ASCENDIS HAS RECEIVED AN UNSOLICITED OFFER IN RESPECT OF ITS REMEDICA BUSINESS UNIT BASED IN CYPRUS.CURRENTLY INVOLVED IN NEGOTIATIONS REGARDING UNSOLICITED OFFER IN RESPECT OF ITS REMEDICA BUSINESS UNIT.  Full Article

Ascendis Health Identifies Pharma And Consumer Healthcare As Core Focus Areas
Tuesday, 25 Sep 2018 

Sept 25 (Reuters) - Ascendis Health Ltd ::JSE: ASC - ASCENDIS HEALTH ADOPTS NEW STRATEGIC FOCUS.ASCENDIS HEALTH LTD - PHARMA AND CONSUMER HEALTHCARE HAVE BEEN IDENTIFIED BY GROUP AS CORE FOCUS AREAS.ASCENDIS HEALTH - PLANS TO DRIVE GEOGRAPHIC EXPANSION AND GROWTH BY STRENGTHENING ITS CURRENT FOOTHOLD IN EUROPE, MIDDLE EAST AND AFRICA.ASCENDIS HEALTH LTD - STRATEGIC NON-CORE BUSINESSES SHOULD BE DIVESTED TO ENSURE GREATER FOCUS ON CORE OPERATIONS.ASCENDIS HEALTH - BIOSCIENCES IDENTIFIED AS NON-CORE AND LOGICAL NEXT STEP IS FOR ASCENDIS HEALTH TO DIVEST FROM BUSINESS.ASCENDIS HEALTH LTD - CORE BUSINESSES WILL BE COMPLEMENTED BY TWO SOLID PERFORMING DIVISIONS, MEDICAL AND ANIMAL HEALTH.ASCENDIS HEALTH LTD - OPERATING MODEL WILL SHIFT FROM CURRENT GEOGRAPHIC STRUCTURE, FOCUSED ON SOUTH AFRICA AND EUROPE, TO A GLOBAL DIVISIONAL MODEL.ASCENDIS HEALTH LTD - GROUP'S TARGETED OBJECTIVE IS TO GENERATE A 7% TO 10% ORGANIC REVENUE GROWTH RATE BY 2023 FINANCIAL YEAR.ASCENDIS HEALTH - TARGETED OBJECTIVE IS TO GENERATE 22% TO 25% EBITDA MARGIN BY 2023 FINANCIAL YEAR.ASCENDIS HEALTH - FOUR ASSETS WHICH ARE EITHER NON-CORE TO LONGER-TERM STRATEGY OR NOT PERFORMING OPTIMALLY HAVE BEEN IDENTIFIED FOR DIVESTMENT.ASCENDIS HEALTH LTD - ASSETS IDENTIFIED FOR DIVESTMENT INCLUDE BIOSCIENCES BUSINESS.ASCENDIS HEALTH LTD - IN FINAL STAGES OF CONCLUDING A SALE AGREEMENT FOR ISANDO MANUFACTURING FACILITY.ASCENDIS HEALTH LTD - AGREEMENT HAS BEEN REACHED FOR SALE OF ASCENDIS DIRECT FOR R40 MILLION.  Full Article

Ascendis Health FY Normalised HEPS 159.7 Cents
Tuesday, 25 Sep 2018 

Sept 25 (Reuters) - Ascendis Health Ltd ::FY REVENUE UP 21% TO R7.7 BILLION; FY NORMALISED HEPS UP 2% TO 159.7 CENTS.  Full Article

Ascendis Health Announces Update On Strategic Business Review And Change In Directors
Monday, 25 Jun 2018 

June 25 (Reuters) - Ascendis Health Ltd ::INVESTOR UPDATE ON STRATEGIC BUSINESS REVIEW AND CHANGE IN DIRECTORS.DURING INITIAL PHASE OF STRATEGIC REVIEW MANAGEMENT IDENTIFIED THREE ASSETS FOR DIVESTMENT.GROUP HAS DECIDED TO FOCUS SOLELY ON ITS BIGGEST SPORTS NUTRITION BRAND, SCITEC.PROCEEDS FROM DISPOSAL OF THESE ASSETS WILL BE REINVESTED IN BUSINESS TO FURTHER IMPROVE ORGANIC REVENUE GROWTH AND FINANCIAL RETURNS.NO LONGER PLANS TO OFFER ITS LOCAL PORTFOLIO OF FIVE SPORTS NUTRITION BRANDS IN SOUTH AFRICAN MARKET.HAS DECIDED TO DIVEST ASCENDIS SPORTS NUTRITION IN SOUTH AFRICA AND HAS INITIATED A SALE PROCESS TO DISPOSE OF BUSINESS.PLANNED FOR ASN TO BE SOLD AS A GOING CONCERN AND IT IS EXPECTED THAT ALL OF ITS STAFF WILL TRANSFER TO NEW OWNERS.CLIFF SAMPSON WILL BE RETIRING AS AN EXECUTIVE DIRECTOR AND MANAGING DIRECTOR OF GROUP'S SOUTH AFRICAN OPERATIONS ON 30 JUNE 2018.TO DISPOSE OF ASCENDIS DIRECT AS A GOING CONCERN AND HAS INVITED OFFERS FROM POTENTIAL BUYERS.DECIDED TO APPOINT AN INTERIM CHIEF OPERATING OFFICER TO LEAD SOUTH AFRICAN BUSINESS UNTIL STRATEGIC REVIEW PROCESS HAS BEEN COMPLETE.TO RETAIN GOOD MANUFACTURING PRACTICE APPROVED PHARMACEUTICAL MANUFACTURING FACILITY LOCATED IN WYNBERG, JOHANNESBURG, RATHER THAN ISANDO.APPOINTMENT OF MARNUS SONNEKUS AS INTERIM COO SOUTH AFRICA WITH EFFECT FROM 1 JULY 2018, BASED IN JOHANNESBURG.ASCENDIS HEALTH LTD - PLANS TO SELL ITS 23 000 M² GMP PHARMACEUTICAL MANUFACTURING FACILITY IN ISANDO.  Full Article

Ascendis Health announces acquisition of Kyron Laboratories Proprietary Ltd​
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Ascendis Health Ltd ::‍ACQUISITION OF 100% OF KYRON LABORATORIES PROPRIETARY LIMITED​.DEAL ‍FOR A CONSIDERATION OF R396.4 MILLION UPFRONT PLUS A PERFORMANCE-BASED DEFERRED PORTION FROM NIXSIM PROPRIETARY LIMITED​.‍PURCHASE CONSIDERATION IS LIMITED TO A MAXIMUM OF R450 MILLION​.  Full Article